About the Company
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KMPH News
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2. ZVRA isn't one of the 30 most popular stocks among hedge funds at the end of the third ...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price Target
Last week saw the newest yearly earnings release from Zevra Therapeutics, Inc. (NASDAQ:ZVRA), an important milestone in the company's journey to build a stronger business. Revenues were a bright ...
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its ...
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled ...
Zevra Therapeutics Inc (ZVRA) Stock: Analyzing the Market Value
Clifton R. LaDuane, the CFO, Secretary & Treasurer of Zevra Therapeutics Inc, purchase 1,000 shares at $4.96 during a trade that took place back on Sep 06 ’23, which means that Clifton R. LaDuane is ...
Zevra Therapeutics: Q4 Earnings Snapshot
CELEBRATION, Fla. — CELEBRATION, Fla. — Zevra Therapeutics, Inc. (ZVRA) on Thursday reported a loss of $15.2 million in its fourth quarter. The Celebration, Florida-based company said it had a ...
Zevra Therapeutics Inc ZVRA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 Zevra Therapeutics Inc Earnings Call
Nichol Ochsner; Vice President of Investor Relations & Corporate Communications; Zevra Therapeutics Inc Neil McFarlane; President & CEO; Zevra Therapeutics Inc LaDuane Clifton; CFO, Secretary ...
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
Good afternoon, everyone. Thank you for joining the Zevra Therapeutics' Q4 2023 Corporate Updates and Financial Results Call. Today's call is being recorded. It will be made available the company ...
Loading the latest forecasts...